Trial Profile
A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Stempeutics
- 05 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Feb 2017 New trial record